Feds Dump Hollis-Eden's Radiation Drug - Smartmoney.com
March 8, 2007| Feds Dump Hollis-Eden's Radiation Drug Smartmoney.com - Next-generation candidates related to Neumune are being licensed by the company for conditions such as diabetes and rheumatoid arthritis. ... Government Nukes Hollis-Eden's Radiation Drug Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP ... Feds won't buy drug to combat ills of radiation |
The Immune Response Corporation Injects First Patient in Trial of ... - PharmaLive.com (press release)
March 8, 2007| The Immune Response Corporation Injects First Patient in Trial of ... PharmaLive.com (press release), PA - NeuroVax(TM) may represent a significant advance in the treatment of MS, which affects more than 2.5 million people worldwide, including more than 400000 in ... |
Significant Phase III Results With CIMZIA(TM) in Rheumatoid Arthritis - Drug Newswire (press release)
March 8, 2007| Significant Phase III Results With CIMZIA(TM) in Rheumatoid Arthritis Drug Newswire (press release), CT - ... on CIMZIA(TM) (certolizumab pegol), the first PEGylated, Fc-free anti-TNF, intended for the treatment of moderate to severe rheumatoid arthritis (RA). ... |
EntreMed to Present at the 6th Annual North America Forum for ... - PR Newswire (press release)
March 8, 2007| EntreMed to Present at the 6th Annual North America Forum for ... PR Newswire (press release), NY - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
The Immune Response Corporation Injects First Patient In Trial Of ... - Medical News Today (press release)
March 8, 2007| The Immune Response Corporation Injects First Patient In Trial Of ... Medical News Today (press release), UK - NeuroVax(TM) may represent a significant advance in the treatment of MS, which affects more than 2.5 million people worldwide, including more than 400000 in ... |